Amgen Inc. buy BMO Capital Markets
Start price
19.12.23
/
50%
€253.60
Target price
19.12.24
€297.31
Performance (%)
-1.16%
End price
20.12.24
€250.65
Summary
This prediction ended on 20.12.24 with a price of €250.65. With a performance of -1.16%, the BUY prediction by BMO_Capital_Markets finished with a loss. BMO_Capital_Markets has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. Dividends of €8.32 are taken into consideration when calculating the performance. BMO_Capital_Markets has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Amgen Inc. | -4.430% | -4.430% | 3.419% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
Comments by BMO_Capital_Markets for this prediction
In the thread Amgen Inc. diskutieren
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $326.00 price target on the stock, up previously from $286.00.
Ratings data for AMGN provided by MarketBeat
In the thread Trading Amgen Inc.
Die von BMO_Capital_Markets gewählte maximale Laufzeit wurde überschritten